Psychological Support Based on Positive Suggestions (PSBPS) on Mental Health Morbidity and Cognitive Function
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04045210 |
Recruitment Status :
Recruiting
First Posted : August 5, 2019
Last Update Posted : October 12, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Critical Illness | Other: Psychological Support Based on Positive Suggestions | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 182 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This will be a tho arm single-center, prospective, randomized, controlled trial comparing the effect of PSBPS vs. no PSBPS on psychological and clinical outcomes in the critically ill population. PSBPS will be administered by trained ICU doulas to eligible patients |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Randomized Controlled Trial to Evaluate Efficacy of Psychological Support Based on Positive Suggestions (PSBPS) on Mental Health Morbidity and Cognitive Function |
Actual Study Start Date : | August 30, 2019 |
Estimated Primary Completion Date : | December 27, 2024 |
Estimated Study Completion Date : | July 18, 2025 |

Arm | Intervention/treatment |
---|---|
No Intervention: No Intervention | |
Experimental: Doula |
Other: Psychological Support Based on Positive Suggestions
Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention. |
- minimal important change in hospital anxiety and depression scale - Anxiety [ Time Frame: within 96 hours after ICU discharge and 3 months after hospital discharge ]This outcome will be evaluated using Hospital Anxiety and Depression Scale (HADS). The total scores range is 0-21 for both depression and anxiety scores. A higher score indicates a worse depression and anxiety. Comparison will be done between the score obtained from the control group and the two intervention groups within 96 hours after ICU discharge and at 6 months follow up
- minimal important change in hospital anxiety and depression scale-Depression [ Time Frame: within 96 hours after ICU discharge and 3 months after hospital discharge ]This outcome will be evaluated using Hospital Anxiety and Depression Scale (HADS). The total scores range is 0-21 for both depression and anxiety scores. A higher score indicates a worse depression and anxiety. Comparison will be done between the score obtained from the control group and the two intervention groups within 96 hours after ICU discharge and at 6 months follow up
- minimal important change in Impact of Event Scale-Revised [ Time Frame: within 96 hours after ICU discharge and 3 months after hospital discharge ]This outcome will be evaluated using Impact of Event Scale-Revised. The total scores range is 0-4. A higher score indicates worse symptoms of post traumatic stress. Comparison will be done between the score obtained from the control group and the two intervention groups within 96 hours after ICU discharge and at 6 months follow up
- statistically significant improvement in MoCA-blind [ Time Frame: within 96 hours after ICU discharge and 3 months after hospital discharge ]This outcome will be evaluated using Montreal cognitive assessment-blind (MoCA-blind). The total scores range is 0-22. A higher score indicates better cognitive function. Comparison will be done between the score obtained from the control group and the two intervention groups within 96 hours after ICU discharge and at 6 months follow up
- EQ-5D-3L [ Time Frame: within 96 hours after ICU discharge and 3 months after hospital discharge ]Health questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Critically ill adult patients (age >18) requiring non-invasive ventilation, high flow O2 or mechanical ventilation and expected to stay >48 hours.
Exclusion Criteria:
- history of dementia
- intellectual disability
- suicide attempt
- psychotic disorders such as schizophrenia
- acute alcohol/substance intoxication or withdrawal
- severe metabolic encephalopathy
- patients on comfort care
- Patients not expected to survive the hospital stay
- Non-English speaking.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04045210
Contact: ACRU | 866-265-9263 | Karnatovskaia.Lioudmila@mayo.edu |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 |
Responsible Party: | Lioudmila Karnatovskaia, Principal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT04045210 |
Other Study ID Numbers: |
19-004660 |
First Posted: | August 5, 2019 Key Record Dates |
Last Update Posted: | October 12, 2022 |
Last Verified: | October 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Critical Illness Disease Attributes Pathologic Processes |